Lundbeck and Teva receive EU marketing authorisation for new drug  

2005.02.24
Denmark's Lundbeck and its Israeli partner Teva Pharmaceutical Industries, have received EU marketing authorisation for Azilect, a new drug for the treatment of Parkinson's disease

Danish pharmaceutical company Lundbeck and its Israeli collaboration partner Teva Pharmaceutical Industries, have received EU marketing authorisation for Azilect, a new drug for the treatment of Parkinson's disease. Azilect is a novel 2nd generation, selective, irreversible monoamine oxidase type-B inhibitor which blocks the breakdown of dopamine in the brain.

 

Lundbeck and Teva plan to market the new drug in a number of European countries from Q2 2005. It is estimated that approx. 1 million people in the EU suffer from Parkinson's disease. In 2003, global sales of drugs for the treatment of Parkinson's disease amounted to DKK 12.4 bn (USD 2.2 bn), of which 40% was generated in Europe. The news is reported by financial daily newspaper Børsen and on Lundbeck's website.

 

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×